STAAR Surgical (NASDAQ:STAA) has been given an average rating of “Hold” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $46.00.
Several equities analysts have weighed in on the stock. BidaskClub lowered shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Friday, August 2nd.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its position in shares of STAAR Surgical by 483.3% in the 2nd quarter. Royal Bank of Canada now owns 1,190 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 986 shares during the last quarter. TRUE Private Wealth Advisors purchased a new stake in shares of STAAR Surgical in the 2nd quarter valued at approximately $36,000. Aperio Group LLC purchased a new stake in shares of STAAR Surgical in the 2nd quarter valued at approximately $43,000. Aspire Private Capital LLC purchased a new stake in shares of STAAR Surgical in the 1st quarter valued at approximately $51,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of STAAR Surgical in the 2nd quarter valued at approximately $46,000. 90.87% of the stock is currently owned by hedge funds and other institutional investors.
STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $39.66 million for the quarter, compared to analyst estimates of $40.10 million. STAAR Surgical had a net margin of 5.80% and a return on equity of 12.81%. As a group, analysts anticipate that STAAR Surgical will post 0.33 earnings per share for the current year.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Featured Article: Put Option Volume
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.